AWARDS
ALTHEA PSILOCYBIN OUTCOMES AWARDS
Chariot is the proud recipient of two 2025 Althea Psilocybin Outcomes Awards. The inaugural awards recognize those delivering exceptional outcomes, “grounded not in opinion or hype, but in real participant-reported data: improvements in mental health, experiences of mystical insight, feelings of safety, and trust in the people guiding the journey.”
Chariot was recognized as:
THE ANXIETY ALLEVIATION LEADER
The service center whose clients reported the most significant reduction in anxiety symptoms, as measured by the GAD-7 (Generalized Anxiety Disorder scale). This distinction reflects the power of safe, intentional psychedelic facilitation to help clients find calm, clarity, and emotional ease.
THE SAFE PASSAGE AWARD
Honors the center whose clients reported the strongest sense of safety throughout their psilocybin experience. Those who provide not just a service, but a sanctuary—creating containers where trust, care, and professionalism allow deep healing to unfold.
WE ARE ALSO PROUD TO WORK WITH FOUR OF THE SIX INCREDIBLE FACILITATOR AWARDEES
Evelyn Cushing, Well-Being Improvement Award; Dr. Olivia Hicks, Client Choice Award; Kayli Howard, Client Choice Award, and; Erin Baldwin Draper, MSW, Safe Passage Award.
Honors & Media Recognition
EXPLORE PRESS FEATURES, PODCASTS, & AWARDS RECOGNIZING CHARIOT’S WORK
As seen in:
PRESS
STUDIES CONDUCTED AT CHARIOT
MATTHEW & OLIVIA HICKS LOW INCOME FOR DEPRESSION STUDY
"This feasibility study demonstrated that a low-income population with depression can really benefit from psilocybin therapy done in a group. It was safe, it was well-tolerated, and we saw really meaningful improvements in their lives," said Dr. Olivia Hicks, also from NUNM.
"The effects of just two small treatments can have months, if not years, of effect on people and improve so many other aspects of their lives," Olivia Hicks continued. "Often in medication trials, we hear about all of the horrible side effects of medications ... they fix one problem — but then, create 10 others.
"What we're seeing with psilocybin and other psychedelics is that we get side improvements. Not only does the depression get better, but so does the sleep, so does family relationships, so does one's ability to just show up in the world and work."
One of the organizations which helped fund the study has an aggressive goal of getting health insurance companies involved in reimbursing for psilocybin therapy by 2030, arguing that it can actually save money in the long run for treating mental illness.
Another study at OHSU is underway, looking at the longer-term outcomes from psilocybin therapy. That's expected to wrap later this year.
Portland Business Journal | NBC/KGW | NUNM | ClinicalTrials.gov
